drugset / Trial / NCT05092386
Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
RandomizedParallel-groupDouble-blindPrevention
Summary
This study is an open-label combined randomized double-blind, positive control phase Ⅰ clinical trial of the a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine manufactured by Sinovac Research \& Development Co., Ltd. The purpose of this study is to preliminary evaluate the safety and immunogenicity of the study vaccine
Timeline
- Start
- 2023-01-03
- Primary completion
- 2024-05-26
- Completion
- 2024-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pfizer PCV13 | Vaccine | 0.5 ml | — |
| Subject | Prevnar 13 | Vaccine | 0.5 ml | — |
| Comparator | WALVAX PCV13 | Vaccine | 0.5 ml | — |